OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
27
Results
Show all
Save search
Copy query
Show results for
Unknown
(27)
Publication Date
Release Date
2022
(6)
2023
(5)
2021
(4)
2025
(2)
2024
(2)
2016
(2)
2026
(1)
2020
(1)
2018
(1)
2014
(1)
2011
(1)
2009
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Not available
S-EPMC4966513
|
biostudies-literature
Cite
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Not available
S-EPMC4798896
|
biostudies-literature
Cite
Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis.
Not available
S-EPMC4217133
|
biostudies-literature
Cite
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function.
Not available
S-EPMC3267376
|
biostudies-literature
Cite
The FLUXNET2015 dataset and the ONEFlux processing pipeline for eddy covariance data.
Not available
S-EPMC7347557
|
biostudies-literature
Cite
Mortality results from a randomized prostate-cancer screening trial.
Not available
S-EPMC2944770
|
biostudies-literature
Cite
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425
|
biostudies-literature
Cite
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Not available
S-EPMC9054878
|
biostudies-literature
Cite
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Not available
S-EPMC10830583
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets